Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance

Rui Li1,4, Zhi-gang Yang1,2*, Lin-yi Wen1, Xi Liu1, Hua-yan Xu1,2, Qin Zhang1 and Ying-kun Guo3†

Abstract

Background: Coronary microvascular dysfunction is highly prevalent in patients with amyloid light-chain (AL) cardiac amyloidosis (AL-CA). The aim of this study was to clarify the feasibility of first-pass perfusion imaging using 3 T cardiovascular magnetic resonance (CMR) for evaluating the difference in left ventricular (LV) regional myocardial microvascular function among normal subjects and in patients with AL-CA. The amyloidosis patients were classified into those with impaired systolic function [LV ejection fraction (LVEF) < 50 %] and those with preserved systolic function.

Methods: In total, 32 patients with biopsy-proven AL-CA, including 11 AL-CA patients with systolic dysfunction, 21 AL-CA patients with preserved systolic function, and 25 healthy subjects, underwent CMR examination. LV regional myocardial perfusion parameters included upslope, time to maximum signal intensity (TTM) and max signal intensity (MaxSI) were compared among the three patient groups. Receiver operating characteristic analysis was performed to determine whether perfusion parameters could be used in discriminating regional myocardial microvasculatity between AL-CA patients and normal subjects.

Results: The patients with AL-CA had significantly reduced first-pass perfusion upslope and MaxSI, and increased TTM compared with the normal subjects (all P < 0.01). Compared with the patients with AL-CA and preserved LVEF, the patients with AL-CA and impaired systolic function had a longer TTM in the basal (47.05 ± 16.59 vs. 39.68 ± 19.11; P = 0.002) and mid-ventricular (44.61 ± 16.34 vs. 37.74 ± 18.25; P = 0.002) segments; lower upslope in the basal (2.41 ± 1.32 vs. 3.60 ± 1.68; P < 0.0001), mid-ventricular (2.82 ± 1.34 vs. 4.15 ± 2.02; P < 0.0001), and apical (3.71 ± 1.38 vs. 4.97 ± 2.55; P = 0.004) segments; and lower MaxSI (31.67 ± 15.23 vs. 37.96 ± 11.15; P < 0.0001) in the basal segment. The ROC curve analysis revealed that the first-pass upslope, TTM, and MaxSI may be used as indicators for differentiating microcirculation between AL-CA patients with preserved or impaired systolic function and normal subjects.

(Continued on next page)
Background

Amyloidosis is a rare disorder characterized by the extracellular deposition of pathological insoluble proteins in multiple organs, including the heart [1, 2]. Amyloid light-chain (AL) amyloidosis, in which amyloid fibrils are derived from the monoclonal immunoglobulin light chain, is one of the most common types of amyloidosis [3]. Cardiac involvement, termed cardiac amyloidosis (CA), is observed in approximately 50% of patients with systemic amyloidosis and is also the major cause of death in patients with AL amyloidosis [4, 5]. AL-CA has a poor prognosis, particularly in patients with impaired systolic function and abnormal wall thickening. The left ventricular ejection fraction (LVEF), which is widely used as an index of systolic function in clinical practice, is considered an independent predictor of cardiac mortality in AL amyloidosis [3, 4].

Necroscopy examinations have confirmed that amyloid infiltration in the microvascular system may cause coronary microcirculation disorder, with patients presenting with symptoms of angina and signs of ischemia [6–8]. In addition, increased wall thickness, an important morphologic feature of CA, may affect myocardial microvascular perfusion due to vascular rarefaction and compression [9].

As amyloid infiltration in the cardiac microvascular system is prevalent in patients with CA and is potentially associated with LV systolic function and wall thickening [3, 9], it is essential to evaluate coronary microvascular perfusion in patients with AL-CA, particularly in those with systolic dysfunction. Clinically, contrast-enhanced cardiovascular magnetic resonance (CE-CMR) is regarded as a well-established method for the assessment of cardiac morphology, function, and tissue characteristics [10, 11]. High field 3 T CMR improves the signal to noise ratio, contrast to noise ratio, and first-pass myocardial perfusion CMR [12, 13]. Higher levels of accuracy, sensitivity, specificity, and reproducibility can be achieved by using CMR perfusion parameters, including slope, TTM, and MaxSI [12, 14, 15]. These parameters, derived from the CMR signal intensity-time curve and reflected myocardial perfusion reserve, are associated with coronary microvascular function [16]. By using a first-pass myocardial perfusion technique, CMR can be used to monitor myocardial microvascular dysfunction in hypertrophic and dilated cardiomyopathy in a non-invasive manner [17, 18]. Additional, CE-CMR imaging allows the simultaneous assessment of both myocardial perfusion and function in a single investigation. However, to the best of our knowledge, few studies have investigated myocardial microvascular dysfunction in patients with AL-CA using CMR. Thus, the aim of this study was to assess regional myocardial perfusion and function in AL-CA patients using 3.0-T CE-CMR imaging and to determine whether these perfusion parameters may assist in discriminating between the microcirculation of AL-CA patients with or without LV systolic dysfunction and that of normal subjects.

Methods

Patients

The institutional ethics committee of our hospital approved this study, and written informed consent was obtained from each participant prior to the investigation. Between September 2013 and March 2015, 38 patients with biopsy-proven AL amyloidosis were enrolled in the study, according to the following inclusion criteria: (a) AL amyloidosis, initially diagnosed in extracardiac tissue using Congo red and immunohistochemical staining and (b) cardiac involvement, confirmed according to echocardiographic criteria [19]. The exclusion criteria included (a) associated diseases that may cause myocardium hypertrophy and/or coronary microvascular dysfunction, such as hypertrophic cardiomyopathy, diabetes, hypertension, coronary artery disease, and arrhythmia and (b) non-interpretable MR image quality, unsuitable to enable diagnosis. In total, 32 AL-CA patients remained following the exclusion of six patients who met the aforementioned exclusion criteria. The mean patient age was 60 years (range, 38–75 years). In total, 15 of the 32 patients (47.7%) were women. During the same period, 25 normal controls (13 males and 12 females; mean age, 37.68 ± 11.94 years; range, 17–58 years) underwent CMR on initial clinical suspicion of cardiovascular disease but were confirmed as healthy subjects by clinical evidence and served as a control group. The exclusion criteria included chronic disease, family history of cardiovascular disease, diabetes, hypertension (>140/90 mmHg), and arrhythmia. Prior to CMR, routine clinical echocardiography was performed in all subjects.

Conclusions: The differences in LV regional myocardial microvascular function among normal subjects, AL-CA patients with systolic dysfunction, and AL-CA patients with preserved systolic function can be monitored using first-pass perfusion CMR.

Keywords: Amyloid light-chain cardiac amyloidosis, Cardiovascular magnetic resonance, Perfusion imaging, Left ventricular function, Coronary microvascular function
using two-dimensional transthoracic echocardiography (TEE) with a multiplanar 3.5-MHz probe (IE33; Philips Medical Systems, Andover, MA, USA), according to the guidelines of the American Society of Echocardiography [20]. Endomyocardial biopsy was not performed in our study due to its invasive nature and the severity of its potential complications [21]. Thus, the patients were diagnosed with CA via extracardiac tissue biopsy, which was obtained through specimens of kidney \((n = 6; 18.8\%)\), bone marrow \((n = 27; 84.4\%)\), liver \((n = 1; 3.1\%)\), fat \((n = 6; 37.5\%)\), rectum \((n = 1; 3.1\%)\), skin \((n = 5; 15.6\%)\), and tongue \((n = 1; 3.1\%)\) and typical echocardiographic findings, including a mean wall thickness of the ventricular wall and/or interventricular septum measuring >12 mm in diastole [19].

**CMR**

All patients were examined in the supine position using a 3 T whole-body scanner (Trio Tim; Siemens Medical Solutions, Erlangen, Germany) at least 3 days following ECG examination. A dedicated two-element cardiac-phased array coil was used for signal detection. The manufacturer’s standard ECG-triggering device and the breath-hold technique were used to monitor the individuals’ ECG values and breathing, respectively. Following a survey scan, cine images were acquired in 2-chamber, 3-chamber, and 4-chamber views using a TrueFISP sequence \((TR/TE, 44.7/1.33\text{ ms}; \text{flip angle}, 50^\circ; \text{field of view}, 290 \text{ mm} \times 373 \text{ mm}; \text{matrix size}, 146 \text{ mm} \times 224 \text{ mm}; \text{slice thickness}, 8 \text{ mm})\). Subsequently, gadobenate dimeglumine (MultiHance; 0.5 mmol/ml; Bracco, Milan, Italy) was intravenously injected using an automated injector (Stellant, MEDRAD, Indianola, PA, USA) at a dose of 0.1 ml/kg body weight and a flow rate of 2.5–3.0 ml/s. In addition, a 20 ml saline flush was injected immediately following contrast at a rate of 3.0 ml/s. Rest regional perfusion images were acquired in three standard short-axis slices (apical, middle, and basal) and in one slice of the 4-chamber view using an inversion-recovery prepared echo-planar imaging sequence \((\text{repetition time}, 200 \text{ ms}; \text{echo time,} 1.1 \text{ ms}; \text{inversion time,} 90.0 \text{ ms}; \text{flip angle,} 10^\circ; \text{field of view}, 270 \text{ mm} \times 360 \text{ mm}; \text{acquisition matrix}, 106 \times 192; \text{slice thickness,} 8 \text{ mm})\). Each set of first-pass perfusion images was completed in 80 cardiac cycles.

**CMR data analysis**

Image analysis was performed offline using commercial software (cvi42; Circle Cardiovascular Imaging, Inc., Calgary, Canada). Endocardial and epicardial traces were performed manually by two experienced observers (Wen LY and Li R) in the serial short-axis slices at the end-diastolic and end-systolic phases. The global cardiac function, including LV end-diastolic volume (EDV), end-systolic volume (ESV), and LV ejection fraction (LVEF) were computed using a modified Simpson’s rule. For regional analysis, a 16-segment mode (Bull’s eye plot), according to AHA standard segmentation, was constructed on the basis of analysis of the long- and short-axis slices (apical, mid-ventricular, and basal; Fig. 1), which included four apical segments (septum, anterior, lateral, and inferior), and six mid-ventricular and basal segments (inferior septum, anterior septum, anterior, anterolateral, inferolateral, and inferior). Morphologically, the average LV end-diastolic and end-systolic wall thickness for each segments were measured, and the myocardial wall thickening, defined as the variation in thickness between diastole to systole, expressed as a percentage \((Wth)\) were calculated using the centerline method [22]. For evaluation of the LV regional perfusion, the endocardial, epicardial, and blood pool contours of all three sets of first-pass perfusion images (basal, mid-ventricular,
and apical) were delineated manually, and the myocardial signal intensity-time curve was processed using the aforementioned software. First-pass parameters including upslope, time to maximum signal intensity (TTM) and max signal intensity (MaxSI) were consequently obtained from the myocardial signal intensity-time curve (Fig. 2).

**Statistical analysis**

All statistical analyses were performed using SPSS software (version 19.0 for Windows; SPSS, Chicago, IL, USA). The results are expressed as the mean ± standard deviation (SD). Continuous variables were compared using independent Student’s t-test or one-way analysis of variance (ANOVA). A Mann–Whitney U test was used to compare the regional myocardial perfusion and functional parameters among the normal subjects and the AL-CA patients with or without systolic dysfunction using Bonferroni’s correction for multi-group comparisons. If a significant difference was confirmed, receiver operating characteristic (ROC) analysis was performed to determine whether the cut-off values of regional cardiac perfusion can be used to differentiate myocardial microvascular function between AL-CA patients and normal subjects. Spearman’s rank correlations analysis was performed to examine the correlation between regional myocardial perfusion, wall thickness, and wall thickening. \( P < 0.05 \) was considered to indicate a statistically significant difference.

**Results**

**Baseline characteristics**

The baseline characteristics the AL-CA patients and normal subjects are presented in Table 1. Of the 32 cardiac patients, 11 (34.4 %) presented with impaired systolic function (LVEF < 50 %). Half of the AL-CA patients had a history of New York Heart Association functional class ≥ III heart failure. The LVEDV of the AL-CA patients with preserved LVEF was lower than that of the normal healthy controls \( (P = 0.013) \). The AL-CA patients with impaired LVEF had a significantly higher LVESV and lower SV than that of the normal subjects and the AL-CA patients with preserved LVEF \( (all \ P < 0.001) \). However, no statistically significant differences were observed between the patients with preserved LVEF and the normal subjects in LVESV \( (47.45 \pm 12.97 \text{ vs. } 52.62 \pm 14.01 \text{ ml}; P = 0.693) \) or LVEF \( (56.62 \pm 9.43 \text{ vs. } 60.18 \pm 4.30 \text{ %}; P = 0.059) \). The LV mass in the AL-CA patients were markedly increased as compared with that in the normal subjects (both \( P < 0.0001 \)); however, there was no significant difference between the AL-CA patients with LV systolic dysfunction and those without LV systolic dysfunction \( (143.55 \pm 42.64 \text{ vs. } 127.14 \pm 32.29 \text{ g}; P = 0.484) \). After CMR and echocardiography, fifteen (46.9 %) patients received chemotherapy whereas seventeen (53.1 %) did not, and the chemotherapy regimen was listed in Table 2.

**LV wall functional analysis**

The AL-CA patients had significantly thicker EDWT and ESWT and reduced Wth compared with the normal controls \( (all \ P < 0.05; \text{ Table 3}) \). Compared with the AL-CA patients with preserved LVEF, the AL-CA patients with LV systolic dysfunction presented with reduced Wth \( (P < 0.0001) \) and increased EDWT \( (P = 0.014) \). However, there was no significant difference in ESWT between the AL-CA patients with LV systolic dysfunction and those without LV systolic dysfunction. Using

---

**Fig. 2** The signal intensity-time curve derived from myocardial perfusion images. The first-pass perfusion values including MaxSI (a), time to max signal intensity (b) and first-pass perfusion upslope (c) were automatically obtained.
the Bull's eye plot, baso-apical gradients of decreased EDWT and ESWT and increased Wth were observed in the AL-CA patients. The average differences in EDWT, ESWT, and Wth in the basal, mid-ventricular, and apical segments between the AL-CA patients with or without LV systolic dysfunction were compared (Table 4). The AL-CA patients with LV systolic dysfunction presented with lower Wth in the basal and mid-ventricular segments as compared with the AL-CA patients with preserved LVEF (27.70 ± 23.11 vs. 48.91 ± 39.54; P = 0.001 and 65.00 ± 44.18 vs. 86.30 ± 52.67; P = 0.007, respectively) and thicker EDWT in the basal segment (13.90 ± 3.11 vs. 12.85 ± 3.76; P = 0.02). However, no significant differences in ESWT were observed between the AL-CA patients with or without LV systolic dysfunction in any of the three segments.

Table 1 Baseline Differences Between Cardiac Normal healthy, AL-CA patients with or without LV systolic dysfunction

|                     | Normal subjects (n = 25) | CA without SD (n = 21) | CA with SD (n = 11) |
|---------------------|--------------------------|------------------------|---------------------|
| Age (Y)             | 37.68 ± 11.94            | 60.10 ± 7.85           | 59.82 ± 12.14       |
| Male                | 13 (52)                  | 11 (52)                | 6 (55)              |
| NYHA functional class|                         |                        |                     |
| I                   | -                        | 2 (9)                  | 0 (0)               |
| II                  | -                        | 10 (48)                | 4 (36)              |
| III                 | -                        | 9 (43)                 | 5 (46)              |
| IV                  | -                        | 0 (0)                  | 2 (18)              |
| Echocardiography    |                          |                        |                     |
| Septal thickness (mm)| 8.73 ± 1.55              | 15.29 ± 2.83           | 17.27 ± 2.57        |
| E/A                 | 1.2 ± 0.2                | 1.7 ± 0.6              | 2.4 ± 0.8           |
| E/E'                | 11.11 ± 2.21             | 17.14 ± 4.33           | 20.82 ± 5.69        |
| Cine-CMR            |                          |                        |                     |
| LVEDV (ml)          | 133.78 ± 25.43           | 111.06 ± 26.84*        | 118. 20 ± 24.47     |
| LVESV (ml)          | 52.62 ± 14.01            | 47.45 ± 12.97          | 71.95 ± 17.71*      |
| LV SV (ml)          | 81.18 ± 15.29            | 63.60 ± 23.44*         | 46.25 ± 10.78*      |
| LVEF (%)            | 60.18 ± 4.30             | 56.62 ± 9.43           | 39.28 ± 6.39*       |
| LV mass (g)         | 85.32 ± 23.32            | 127.14 ± 32.29*        | 143.55 ± 42.64*     |
| Pericardial effusion| -                        | 12 (57)                | 4 (36)              |
| Pleural effusion     | -                        | 13 (67)                | 7 (63)              |

Notes: The values are the mean ± SD, Numbers in the brackets are percentages. *P < 0.017 versus normal group; §P < 0.0017 versus CA with preserved LVEF.

AL-CA = light-chain amyloid cardiac amyloidosis; SD = systolic dysfunction; LV = left ventricular; EDV = end diastolic volume; ESV = end systolic volume; EF = ejection fraction; SV = stroke volume

Table 2 Chemotherapeutic agents used

| Chemotherapy regimen                                | No. of subjects |
|-----------------------------------------------------|-----------------|
| Cyclophosphamide, thalidomide, dexamethasone        | 4               |
| Cyclophosphamide, thalidomide, dexamethasone/prednisone | 1              |
| Bortezomib, dexamethasone, cyclophosphamide        | 2               |
| Cyclophosphamide, prednisone/mesna                 | 1               |
| Cyclophosphamide, prednisone                        | 2               |
| Cyclophosphamide, prednisone/dexamethasone         | 1               |
| Cyclophosphamide, dexamethasone, vinodesine, epirubicin | 1              |
| Cyclophosphamide, dexamethasone                     | 1               |
| Thalidomide, dexamethasone                          | 1               |
| Bortezomib, prednisone                             | 1               |
| None                                                | 17              |

Table 3 First-pass perfusion and regional function data of all study groups

|                     | Normal controls (n = 25) | CA without SD (n = 21) | CA with SD (n = 11) |
|---------------------|--------------------------|------------------------|---------------------|
| Upslope             | 6.64 ± 2.03              | 4.15 ± 2.11*           | 2.89 ± 1.43*        |
| TTM (sec)           | 20.35 ± 13.74            | 39.00 ± 18.60*         | 45.81 ± 16.25*      |
| MaxSI               | 52.74 ± 12.10            | 42.08 ± 12.79*         | 38.21 ± 13.43*      |
| EDWT (mm)           | 6.92 ± 1.99              | 10.28 ± 3.87*          | 11.06 ± 3.72*       |
| ESWT (mm)           | 12.71 ± 3.51             | 16.74 ± 3.59*          | 16.29 ± 3.91*       |
| Wth(%)              | 93.18 ± 62.07            | 77.97 ± 53.05*         | 58.64 ± 50.59*      |

Notes: The values are the mean ± SD, *P < 0.017 versus normal group, §P < 0.0017 versus CA without systolic function; SD = systolic dysfunction; TTM = time to max; EDWT = end-diastole wall thickness; ESWT = end-systole wall thickness; Wth = wall thickening
### Table 4
Regional comparison of first perfusion and function parameters between AL-CA subject with or without LV systolic dysfunction

| Region       | Basal                   | Mid-ventricular         | Apex                     |
|--------------|-------------------------|-------------------------|--------------------------|
|              | Normal                  | CA without SD          | CA with SD               | Normal          | CA without SD          | CA with SD               |
|              | Upslope                 | 6.52 ± 1.85             | 3.60 ± 1.68              | 2.41 ± 1.32      | 6.57 ± 2.07           | 4.15 ± 2.02              | 2.82 ± 1.34              | 6.95 ± 2.22     | 4.97 ± 2.55       | 3.71 ± 1.38      |
|              | TTM (sec)               | 19.51 ± 9.68            | 39.68 ± 19.11            | 47.05 ± 16.59    | 19.78 ± 16.94         | 37.74 ± 18.25            | 44.61 ± 16.34            | 22.47 ± 13.47 | 39.88 ± 18.46    | 45.75 ± 15.83    |
|              | MaxSl                   | 51.17 ± 10.86           | 37.96 ± 11.15            | 31.67 ± 15.23    | 52.96 ± 12.20         | 41.61 ± 12.18            | 38.07 ± 18.24            | 53.96 ± 13.62 | 48.95 ± 13.24    | 48.21 ± 18.63    |
|              | EDWT (mm)               | 8.36 ± 1.88             | 12.85 ± 3.76             | 13.90 ± 3.11     | 6.71 ± 1.44           | 9.82 ± 3.08              | 10.41 ± 3.02             | 5.08 ± 1.00    | 7.09 ± 2.04      | 7.77 ± 1.96      |
|              | ESWT (mm)               | 13.86 ± 3.99            | 18.00 ± 3.63             | 17.43 ± 3.81     | 12.86 ± 2.80          | 17.14 ± 3.40             | 16.39 ± 3.97             | 10.75 ± 2.84   | 14.27 ± 3.45     | 14.44 ± 3.29     |
|              | Wth(%)                  | 72.14 ± 59.86           | 48.91 ± 39.54            | 27.70 ± 23.11    | 97.47 ± 53.27         | 86.30 ± 52.67            | 65.00 ± 44.18            | 118.29 ± 67.79 | 109.06 ± 49.61   | 95.51 ± 61.16    |

**Notes:** The values are the mean ± SD, other abbreviations are the same as in Tables 1 and 2. *P < 0.017 versus normal group; †P < 0.017 versus CA without systolic dysfunction.
First pass perfusion analysis
The first-pass perfusion parameters of all subjects are shown in Table 3. Using the Bull’s eye mode with regional wall functional analysis, the average first perfusion parameters of the basal, mid-ventricular, and apical segments were calculated (Table 4). Gradual increases in upslope and MaxSI, from base to apex, were observed in the AL-CA patients, regardless of LVEF. Compared with the normal controls, the upslope and MaxSI of the AL-CA patients were significantly reduced, and the TTM was significantly increased (all $P < 0.01$). The AL-CA patients with LV systolic dysfunction exhibited a shorter upslope in the three segments (all $P < 0.01$), reduced MaxSI in the basal segment, and longer TTM in the basal and mid-ventricular segments (all $P < 0.01$) as compared with the AL-CA patients without LV systolic dysfunction.

Correlation between regional first-perfusion, wall thickness, and wall thickening
A significant and positive correlation was demonstrated between the first-pass upslope and Wth (Spearman’s rank = 0.258; $P < 0.0001$) and between the MaxSI and Wth (Spearman’s rank = 0.338; $P < 0.0001$). A negative correlation was found between the first-pass perfusion upslope and EDWT (Spearman’s rank = −0.431; $P < 0.0001$) and ESWT (Spearman’s rank = −0.355; $P < 0.0001$) and between the MaxSI and EDWT (Spearman’s rank = −0.458; $P < 0.0001$) and ESWT (Spearman’s rank = −0.288; $P < 0.0001$).

ROC curve analysis
Following ROC analysis in the basal, mid-ventricular, and apical segments, we found that the cut-off values for the first-pass perfusion upslope, TTM, and MaxSI assisted in discriminating between the microvascularity of AL-CA patients with preserved or impaired LVEF and normal controls (Figs. 3 and 4). The area under the ROC curve, and the sensitivity and specificity of the LV regional first by-pass perfusion data used for the discrimination regional myocardial microvascularity between AL-CA patients with or without LV systolic dysfunction and normal controls are summarized in Tables 5 and 6.

Discussion
In this study, we assessed the use of 3 T CMR to provide information on regional myocardial microcirculation and wall abnormalities in AL-CA patients. We found that the TTM, EDWT, and ESWT were increased and the first-pass perfusion slope, MaxSI, and Wth were decreased significantly in the AL-CA patients compared with the normal controls. Furthermore, coronary microvascular dysfunction was significantly correlated with LV wall thickness and wall thickening, which is consistent with a previous report [9]. These findings suggested that myocardial perfusion in AL-CA patients is poorer than that in healthy individuals due to coronary microcirculation disorder. The increased wall thickness and abnormal wall thickening may also contribute to myocardial perfusion dysfunction.

Coronary microvascular dysfunction is common in patients with AL amyloidosis. Symptoms of angina and ischemia, impaired vasodilatation, and minimal coronary vascular resistance have been described in CA patients without coronary artery disease [9, 23–25]. The amyloid deposition leading to coronary microvascular dysfunction in CA patients may be sustained by several pathogenetic mechanisms, including structural (amyloid infiltrated the vascular wall causing wall thickening and luminal obstruction), functional (autonomic and endothelial) and extravascular (perivascular and interstitial amyloid deposits leading to extramural compression and decreased diastolic perfusion time) [9, 26]. In addition, the mechanisms of coronary microvascular dysfunction

![Fig. 3](image_url) Receiver-operating characteristic analysis (ROC) between AL-CA patients with preserved LV systolic function and normal controls. By using the cut-off values of upslope (Green), TTM (Blue) and MaxSI (Red), the first-pass perfusion MR could discriminate the myocardial microvascularity of AL-CA patients with preserved LV systolic function from that of normal controls in the basal (a), mid-ventricular (b) and apex (c) segments.
in other non-ischemic cardiomyopathies, including small-vessel vasculitides, coronary microvascular remodeling, interstitial fibrosis, increased LV end-diastolic pressures and LV myocardial mass, and decreased capillary density may assist in explaining coronary microcirculation disorder in CA [27, 28].

A gradient of basoapically decreasing/increasing slope, MaxSI, and Wth gradient were also observed in the AL-CA patients. This basoapical gradient also reflecting underlying myocardial wall stress in the left ventricle, are in accordance with other CMR findings which showed greater Late Gadolinium Enhancement (LGE) area at the base compared with the apex segments, and echocardiographic studies using strain analysis, which reported reduced basal systolic longitudinal and radial strain in CA [29–32].

Another finding in our study was that the AL-CA patients with impaired LVEF were associated with more marked regional LV microvascular disorder as compared with the AL-CA patients with preserved LVEF. As an independent predictor of cardiac mortality in AL amyloidosis patients, systolic dysfunction tends to occur in advanced stages of the disease and is often associated with poor outcome [4, 33, 34]. AL-CA patients with impairment of systolic function have been considered inappropriate for autologous stem cell transplantation, which is generally accepted as a therapeutic approach to improve the survival rates and quality of life in AL amyloidosis [35–37]. Thus, early identification of the systolic function in AL-CA patients may assist obtaining pretherapeutic information and improve prognosis. Sharmila et al. indicated that the longitudinal strain, reflecting subclinical LV systolic function, is often reduced in CA patients as compared with hypertensive LV hypertrophy, suggesting that the longitudinal dysfunction is linearly associated with microvascular impairment.

**Table 5** ROC analysis of first-pass perfusion for detecting microvascular dysfunction between AL-CA patients with preserved systolic function and normal controls

| Cutoff | AUC  | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) |
|--------|------|-------------------------|-------------------------|
| **Basal segment** | | | |
| Upslope | 5 | 0.888 | 87 (82–93) | 81 (74–87) |
| TTM | 20.8 | 0.843 | 79 (70–85) | 73 (66–80) |
| MaxSI | 42 | 0.816 | 68 (59–76) | 85 (78–90) |
| **Mid-ventricular segment** | | | |
| Upslope | 4 | 0.794 | 58 (49–67) | 90 (84–94) |
| TTM | 19.9 | 0.848 | 85 (78–91) | 67 (59–75) |
| MaxSI | 42 | 0.741 | 58 (49–67) | 82 (75–88) |
| **Apical segment** | | | |
| Upslope | 4 | 0.747 | 52 (41–63) | 94 (87–98) |
| TTM | 21.87 | 0.795 | 77 (67–86) | 70 (60–79) |
| MaxSI | 41 | 0.610 | 37 (27–48) | 86 (78–92) |

Notes: AUC = area under the ROC curve. The abbreviations are the same as in Tables 1 and 2.
Taken together, we hypothesized that coronary microvascular dysfunction is involved in LV systolic impairment and that the evaluation of regional myocardial microcirculation in AL-CA patients may facilitate the early identification of the regional impairment of systolic function.

As significant differences in first by-pass perfusion parameters were observed between the AL-CA patients with impaired or preserved systolic function and the normal controls, these perfusion data may assist in discriminating between the microvascular dysfunction AL-CA patients and normal controls. The data obtained from the ROC analysis supported the use of the upslope, TTM, and MaxSI as criteria to enable the differentiation of the microcirculation of AL-CA patients, regardless of LVEF, from that of normal control individuals. Besides, precise identification of amyloisosis type is also crucial in clinical setting due to the prognosis and the treatment depends on the type of this disease. CMR LGE could help differentiate noninvasively between cardiac light chain amyloid and transthyretin-related amyloidosis (ATTR), and among different ATTR pathogenic mutation groups [29, 38]. As previously research reported, coronary microvascular dysfunction is highly prevalent in cardiac amyloidosis patients regardless of the underlying type of amyloid deposits [9], however, the precise clinical utility of our findings are not clear. Further study is required to determine if myocardial perfusion parameter could help classify the type of cardiac amyloidosis, and may subsequently be an early clinical markers for screening and identification asymptomatic relatives for phenotypic heterogeneity in hereditary ATTR amyloid.

In addition, the process of successful treatment of AL amyloidosis aiming to eliminate or control the dyscrasia that produces the amyloid paraprotein and reflecting by a decrease in cardiac biomarkers, may prior to a change in typical morphologic appearances, and whether coronary microvascular function also response to chemotherapy needs further investigation.

Our study had several limitations. Firstly, a larger sample size of AL-CA patients is required for further investigation, with an emphasis on myocardial perfusion. Secondly, our present study did not evaluate whether the interstitial myocardial fibrosis detected by LGE or quantified by T1 blood-pool gadolinium kinetics or T1 mapping on CMR could affect coronary microvascular dysfunction, which are valuable for differential diagnosis and the prediction of outcomes in CA patients [39–41]. The association between LGE, and T1 blood-pool gadolinium kinetics or T1 mapping, and first-perfusion imaging on CMR in CA patients will be investigated in our future study. Thirdly, resting/exercise electrocardiogram, echocardiography and laboratory examination was performed to exclude coronary heart disease, however, not all AL-CA subjects received coronary angiography in our study, which could help to scientifically prove that ischemia is caused by microvascular dysfunction. Finally, patients with LVEF < 50 % were defined as exhibiting impaired systolic function in our study. However, LVEF reflects the global LV systolic function and is less sensitive in assessing the regional systolic function. In addition, CA patients has smaller cavity sizes (reduced LVEDV) due to increased wall thickness could result in a comparative decrease in EF compared with normal controls, EF may be >50 % in patients with small cavity size result from concentric “hypertrophy”, thus may not accurate to evaluated the systolic function and may consequently mis-classifying some patients with truly impaired systolic function into the normal systolic function group. Dan Liu et al. previously reported that longitudinal

### Table 6: ROC analysis of first-pass perfusion for detecting microvascular dysfunction between AL-CA patients with impaired systolic function and normal controls

| Segment          | Cutoff AUC | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) |
|------------------|------------|--------------------------|--------------------------|
| **Basal segment**|            |                          |                          |
| Upslope          | 4.1        | 0.969                    | 92 (83–98)               | 93 (88–97)              |
| TTM              | 21.9       | 0.932                    | 97 (90–100)              | 76 (68–83)              |
| MaxSI            | 42         | 0.852                    | 79 (67–88)               | 85 (78–90)              |
| **Mid-ventricular segment**| |                          |                          |
| Upslope          | 4          | 0.941                    | 89 (79–96)               | 90 (84–94)              |
| TTM              | 21.68      | 0.941                    | 98 (92–100)              | 77 (69–83)              |
| MaxSI            | 36         | 0.772                    | 61 (48–72)               | 94 (89–97)              |
| **Apical segment**|            |                          |                          |
| Upslope          | 4.57       | 0.906                    | 77 (62–88)               | 94 (87–98)              |
| TTM              | 23         | 0.886                    | 95 (85–99)               | 74 (64–82)              |
| MaxSI            | 43         | 0.638                    | 52 (37–68)               | 77 (68–85)              |

Notes: AUC = area under the ROC curve. The abbreviations are the same as in Tables 1 and 2.
dysfunction was associated with poor outcome in CA patients with preserved LVEF [42]. Therefore, the association between first-pass data and more sensitive indices reflecting the LV systolic function, including strain and pulsed tissue Doppler echocardiography, which can assist in the early identification of systolic dysfunction, will be discussed in our future study.

Conclusions

The difference of LV regional myocardial microvascular function among AL-CA patients with or without LV systolic dysfunction, and normal subjects can be monitored by first-pass perfusion CMR imaging, and the threshold values of LV regional myocardial perfusion parameters may be used as indicators for differentiating myocardial microvascular dysfunction between AL-CA patients with preserved or impaired systolic function and normal subjects.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

LR participated in the study design, contributed to data analysis and interpretation, performed the statistical analysis, and drafted the manuscript. YZG contributed to study design, and contributed to preparation, editing and review of the manuscript. WLY carried out data acquisition, and performed data analysis and interpretation. LX contributed to quantitative data analysis and preparation of the manuscript. XHY participated in data acquisition, contributed to data analysis, and editing of the manuscript. ZQ participated in the study design, contributed to quality control of data and algorithms, and editing and review of the manuscript. All authors read and approved the final manuscript.

Author details

1Department of Radiology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, Sichuan 610041, China. 2National Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 174 Section 3 South Renmin Road, Chengdu, Sichuan 610041, China. 3Department of Radiology, West China Second University Hospital, Sichuan University, 20# Section 3 South Renmin Road, Chengdu, Sichuan 610041, China. 4Department of Radiology, Affiliated Hospital of North Sichuan Medical College, 63# Wenhua Road, Shunqing District, Nanchong, Sichuan 637000, China.

Received: 23 December 2015 Accepted: 29 March 2016

Published online: 06 April 2016

References

1. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(2):180–6.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):908–909.
3. García-Pavía P, Tomé-Éstevez MT, R apezzì C. Amyloidosis. Also a heart disease. Rev Esp Cardiol. 2011;64(9):797–808.
4. Kristen AV, Perz JB, Schonland SO, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2017;19(1):241–5.
5. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–60.
6. Modesto KM, Despresenzi A, Gertz M, et al. Vascular abnormalities in primary amyloidosis. Eur Heart J. 2007;28(8):1019–24.
7. Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polynuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol. 2000;85(7):849–53.
8. Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol. 1979;44(3):413–7.
9. Durbala S, Vangala D, Bruyere Jr J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358–67.
10. Geyer BL, Garot J, Bluemke DA, Wu KC, Lima JA. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation. 2002;106(9):1083–9.
11. Van Hoe L, Vanderheyden M. Ischemic cardiomyopathy: value of different MRI techniques for prediction of functional recovery after revascularization. AJR Am J Roentgenol. 2004;182(1):95–100.
12. Cheng AS, Pegg TJ, Karimnossi TD. et al. Cardiovascular magnetic resonance perfusion imaging at 3 tesla for the detection of coronary artery disease: a comparison with 1.5 tesla. J Am Coll Cardiol. 2007;49(25):2440–9.
13. Jerosch-Herold M. Quantification of myocardial perfusion by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:57.
14. Lawson MA, Bell SP, Adkisson DW, et al. High reproducibility of adenosine stress cardiac MR myocardial perfusion imaging in patients with non-ischaeamic dilated cardiomyopathy. BMJ Open. 2014;4(1):e005984.
15. Mühlberg OM, Dickson ME, Zenovich A, et al. Quantitative magnetic resonance first-pass perfusion analysis: inter- and intraobserver agreement. J Cardiovasc Magn Reson. 2001;3(2):247–56.
16. Nagel E, Klein C, Paetsch I, et al. Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease. Circulation. 2003;108(6):432–7.
17. Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115(18):2418–25.
18. Xu HY, Yang ZG, Sun JY, et al. The regional myocardial microvascular dysfunction differences in hypertrophic cardiomyopathy patients with or without left ventricular outflow tract obstruction assessment with first-pass perfusion imaging using 3.0-T cardiac magnetic resonance. Eur J Radiol. 2014;83(4):665–72.
19. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(3):219–28.
20. Cercques MA, Weissohn N, Bilizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539–42.
21. Pelikka PA, Holmes Jr DR, Edwards WD, Nishimura RA, Tajik AJ, Kyle RA. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med. 1988;148(3):652–6.
22. Sheehan FH, Stewart DK, Dodge HT, Mitten S, Bolon EL, Brown BG. Variability in the measurement of regional left ventricular wall motion from contrast angiograms. Circulation. 1983;68(3):550–9.
23. Al Suvailed J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131(11):838–41.
24. Whitaker DC, Tungkar MF, Dussek JE, Angina with a normal coronary angiogram caused by amyloidosis. Heart. 2004;90(9):e54.
25. Tsaib SL, Seldin DC, Wu H, O’Hara C, Ruberg FL, Sanchorawala V. Myocardial infarction with “clean coronaries” caused by alpamyloid light-chain AL amyloidosis: a case report and literature review. Amyloid. 2011;18(3):160–4.
26. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830–40.
27. Kofflard MJ, Michels M, Krams R, et al. Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics. Neth Heart J. 2007;15(6):209–15.
28. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2006;92(3):357–60.
29. Dungaro JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133–42.
30. Baccouche H, Maunz M, Beck T, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography. 2012;29(6):668–77.
31. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442–8.
32. Balzer P, Furber A, Delépine S, et al. Regional assessment of wall curvature and wall stress in left ventricle with magnetic resonance imaging. Am J Physiol. 1999;277(3 Pt 2):H901–10.
33. Buss SJ, Enami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012;60(12):1067–76.
34. Migino RO, Maseedu RK, Eastwood D, Bowers M, Harmann L, Hari P. Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr. 2009;22(12):1396–402.
35. Perz JB, Schonland SO, Hunderer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127(5):543–51.
36. Skinner M, Sancharawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85–93.
37. Cibeira MT, Sancharawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346–52.
38. Deux JF, Damy T, Rahmouni A, et al. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study. Amyloid. 2014;21(4):246–55.
39. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2013;128(16):1570–9.
40. Banyersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.
41. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.
42. Liu D, Hu K, Stöhr S, et al. Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction. PLoS One. 2014;9(12):e115910.